Corbus Pharmaceuticals Holdings
D

CRBP

3.39000
USD
-0.01
(-0.29%)
مفتوح الان
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
4,188
الربح لكل سهم
-6
العائد الربحي
-
P/E
-1
حجم السوق
69,238,714
أصول ذات صلة

العنوان: Corbus Pharmaceuticals Holdings

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

أسئلة شائعة حول سهم Corbus Pharmaceuticals Holdings